Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer

Taeko Matsuoka; Koji Kawai; Tomokazu Kimura; Takahiro Kojima; Mizuki Onozawa; Jun Miyazaki; Hiroyuki Nishiyama; Shiro Hinotsu; Hideyuki Akaza

doi:10.1007/s00432-014-1856-3

Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer

Taeko Matsuoka, Koji Kawai, Tomokazu Kimura, Takahiro Kojima, Mizuki Onozawa, Jun Miyazaki, Hiroyuki Nishiyama, Shiro Hinotsu, Hideyuki Akaza

University Hospital

Research output: Contribution to journal › Article

3 Citations (Scopus)

Abstract

Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.

Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.

Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).

Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.

Original language	English
Pages (from-to)	759-765
Number of pages	7
Journal	Journal of cancer research and clinical oncology
Volume	141
Issue number	4
DOIs	https://doi.org/10.1007/s00432-014-1856-3
Publication status	Published - Mar 13 2015

Keywords

Combined androgen blockade
Primary androgen deprivation therapy
Prostate cancer
Stage IV

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s00432-014-1856-3

Fingerprint Dive into the research topics of 'Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer'. Together they form a unique fingerprint.

Cite this

Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. / Matsuoka, Taeko; Kawai, Koji; Kimura, Tomokazu; Kojima, Takahiro; Onozawa, Mizuki; Miyazaki, Jun; Nishiyama, Hiroyuki; Hinotsu, Shiro; Akaza, Hideyuki.

In: Journal of cancer research and clinical oncology, Vol. 141, No. 4, 13.03.2015, p. 759-765.

Research output: Contribution to journal › Article

@article{6e3ee7eda9ac43979fdaa4f3aa6a6532,

title = "Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer",

abstract = "Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.",

keywords = "Combined androgen blockade, Primary androgen deprivation therapy, Prostate cancer, Stage IV",

author = "Taeko Matsuoka and Koji Kawai and Tomokazu Kimura and Takahiro Kojima and Mizuki Onozawa and Jun Miyazaki and Hiroyuki Nishiyama and Shiro Hinotsu and Hideyuki Akaza",

year = "2015",

month = mar,

day = "13",

doi = "10.1007/s00432-014-1856-3",

language = "English",

volume = "141",

pages = "759--765",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer

AU - Matsuoka, Taeko

AU - Kawai, Koji

AU - Kimura, Tomokazu

AU - Kojima, Takahiro

AU - Onozawa, Mizuki

AU - Miyazaki, Jun

AU - Nishiyama, Hiroyuki

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

PY - 2015/3/13

Y1 - 2015/3/13

N2 - Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.

AB - Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.

KW - Combined androgen blockade

KW - Primary androgen deprivation therapy

KW - Prostate cancer

KW - Stage IV

UR - http://www.scopus.com/inward/record.url?scp=84925463203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925463203&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1856-3

DO - 10.1007/s00432-014-1856-3

M3 - Article

C2 - 25326347

AN - SCOPUS:84925463203

VL - 141

SP - 759

EP - 765

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -